Raymond James downgraded Editas Medicine (EDIT) to Market Perform from Outperform without a price target The firm cites the company’s extended development timelines and relative uncertainty around its in vivo program development specifics and timelines for the downgrade. Editas recently shifted focus to in vivo editing in sickle cell disease and transfusion-dependent beta thalassemia and the next update for the program is expected in Q1 of 2025, the analyst tells investors in a research note. Raymond James says that while the program may have a safety advantage since it’s not expected to require myeloablative conditioning, this is offset by uncertain efficacy versus the approved ex vivo approach.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine downgraded to Market Perform from Outperform at Raymond James
- Editas Medicine reports Q3 EPS (75c), consensus (75c)
- Is EDIT a Buy, Before Earnings?
- Editas Medicine price target lowered to $9 from $27 at Wells Fargo
- Editas Medicine price target lowered to $12 from $20 at Chardan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
